Clinical Trials Browser

Phase 2 × Lymphoma, Large B-Cell, Diffuse × Dasatinib × Clear all

NCT00918463 2018-08-31

A Study to Evaluate the Safety and Efficacy of Dasatinib (Sprycel) in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 2 Terminated

2 enrolled 7 charts

Lymphoma, Lymphoma, Large B-Cell, Diffuse